257 related articles for article (PubMed ID: 22116994)
1. Membranous glomerulonephritis with the use of etanercept in ankylosing spondylitis.
Kaushik P; Rahmani M; Ellison W
Ann Pharmacother; 2011 Dec; 45(12):e62. PubMed ID: 22116994
[TBL] [Abstract][Full Text] [Related]
2. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
Gorman JD; Sack KE; Davis JC
N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
[TBL] [Abstract][Full Text] [Related]
3. Etanercept: new indication. For ankylosing spondylitis: another option.
Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
[TBL] [Abstract][Full Text] [Related]
6. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature.
Taban M; Dupps WJ; Mandell B; Perez VL
Ocul Immunol Inflamm; 2006 Jun; 14(3):145-50. PubMed ID: 16766397
[TBL] [Abstract][Full Text] [Related]
7. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
[TBL] [Abstract][Full Text] [Related]
8. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
[TBL] [Abstract][Full Text] [Related]
10. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
12. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
Haraoui B; Krelenbaum M
Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of etanercept for treating ankylosing spondylitis].
Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
[TBL] [Abstract][Full Text] [Related]
15. Etanercept-induced Henoch-Schönlein purpura in a patient with ankylosing spondylitis.
Rolle AS; Zimmermann B; Poon SH
J Clin Rheumatol; 2013 Mar; 19(2):90-3. PubMed ID: 23364662
[TBL] [Abstract][Full Text] [Related]
16. Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis.
Castro Rocha FA; Silva FS
J Clin Rheumatol; 2010 Mar; 16(2):81-2. PubMed ID: 20130478
[TBL] [Abstract][Full Text] [Related]
17. Parapharyngeal abscess in a patient receiving etanercept.
Borrás-Blasco J; Nuñez-Cornejo C; Gracia-Perez A; Rosique-Robles JD; Casterá MD; Viosca E; Abad FJ
Ann Pharmacother; 2007 Feb; 41(2):341-4. PubMed ID: 17227824
[TBL] [Abstract][Full Text] [Related]
18. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
Boonen A; van der Heijde D; Severens JL; Boendermaker A; Landewé R; Braun J; Brandt J; Sieper J; van der Linden S
Ann Rheum Dis; 2006 Feb; 65(2):201-8. PubMed ID: 16014677
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
20. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
